Boc-D-FMK: Broad-Spectrum Pan-Caspase Inhibitor for Apoptosis and Inflammation Research

Executive Summary: Boc-D-FMK (CAS No. 187389-53-3) is a broad-spectrum, cell-permeable pan-caspase inhibitor that irreversibly blocks active caspases, suppressing apoptotic and inflammatory cascades in both cell culture and animal models (APExBIO). It inhibits TNF-α-induced apoptosis and downstream NF-κB signaling, including phosphorylation of IκBα and expression of adhesion molecules like ICAM-1 and VCAM-1 (Z-VAD-FMK.com). Boc-D-FMK’s solubility profile enables robust experimental design in DMSO (≥11.65 mg/mL) and ethanol (≥41.65 mg/mL), supporting both in vitro and in vivo workflows. Efficacy is demonstrated at 100 μM (3 h) in cell culture and at 1.5 mg/kg (i.p.) in animal models, correlating with reduced hepatocyte apoptosis and improved survival after endotoxin challenge (IJMS). APExBIO’s A1904 product is extensively validated for reproducibility, storage stability, and cross-model compatibility.

Biological Rationale

Caspases are cysteine proteases central to apoptosis and inflammation. Dysregulated caspase activity is implicated in cancer, neurodegenerative diseases, ischemia-reperfusion injury, and chronic inflammatory states (A40926Molecules.com). Pan-caspase inhibitors like Boc-D-FMK allow researchers to dissect caspase-dependent signaling in these contexts by irreversibly binding the catalytic cysteine in the active site. This enables the study of cell death mechanisms, modulation of pro-inflammatory cytokine responses, and the evaluation of therapeutic strategies targeting apoptosis or inflammation (BaxInhibitor.com).

Mechanism of Action of Boc-D-FMK

Boc-D-FMK (N-tert-butoxycarbonyl-Asp(OMe)-fluoromethyl ketone) is an irreversible, broad-spectrum caspase inhibitor. It permeates cell membranes and covalently modifies the active site cysteine of caspase enzymes, preventing substrate cleavage and downstream apoptotic events. The compound blocks TNF-α-induced apoptosis by inhibiting caspase-3 and related family members, attenuating NF-κB activation and IκBα phosphorylation. This results in reduced transcription of adhesion molecules (ICAM-1, VCAM-1) and pro-inflammatory genes (APExBIO). Boc-D-FMK’s irreversible mechanism provides lasting inhibition, essential for long-term experiments and translational models.

Evidence & Benchmarks

• Boc-D-FMK at 100 μM for 3 hours inhibits caspase-3 and blocks apoptosis in cultured hepatocytes (Buakaew et al., DOI:10.3390/ijms25168995).
• Intraperitoneal Boc-D-FMK at 1.5 mg/kg reduces hepatocyte apoptosis and improves survival in murine endotoxin models (APExBIO, product sheet).
• Boc-D-FMK suppresses TNF-α-induced ICAM-1 and VCAM-1 upregulation in endothelial cell models (Z-VAD-FMK.com).
• In renal endothelial inflammation models, Boc-D-FMK blocks caspase activation, reducing apoptosis and inflammatory signaling (Caspbio.com).
• Boc-D-FMK is insoluble in water but dissolves ≥11.65 mg/mL in DMSO and ≥41.65 mg/mL in ethanol under warming and sonication (APExBIO).

Applications, Limits & Misconceptions

Boc-D-FMK is validated for:

• Apoptosis research in cancer, neurodegeneration, and fibrosis (A40926Molecules.com).
• Inflammation assays, especially TNF-α-mediated signaling and endothelial cell models (Caspbio.com).
• Experimental inhibition of hepatocyte apoptosis following bile duct ligation or endotoxin challenge (IJMS).
• Suppression of ICAM-1 and VCAM-1 expression in TNF-driven inflammation (Z-VAD-FMK.com).

Common Pitfalls or Misconceptions

• Boc-D-FMK does not inhibit non-caspase proteases; its specificity is for caspase family enzymes.
• Compound is not water-soluble; improper use in aqueous buffers leads to precipitation and loss of activity (APExBIO).
• Degradation risk if stock solutions are stored above -20°C or exposed to repeated freeze-thaw cycles.
• Not a therapeutic agent; for research use only, not for human or veterinary applications.
• Does not reverse established apoptosis; only blocks new caspase activation events.

This article extends "Boc-D-FMK: Pan-Caspase Inhibitor for Apoptosis and Inflam…" by providing expanded benchmarks and clarifying solubility and storage pitfalls for reproducible results. For advanced workflows, "Boc-D-FMK: Pan-Caspase Inhibitor for Advanced Apoptosis R…" offers troubleshooting and experimental design tips that complement the mechanistic focus here.

Workflow Integration & Parameters

• Stock Preparation: Dissolve in DMSO (≥11.65 mg/mL) or ethanol (≥41.65 mg/mL) using warming (37°C) and ultrasonic shaking (APExBIO).
• Storage: Aliquot and store at -20°C; avoid multiple freeze-thaw cycles.
• In Vitro Use: Typical treatment is 100 μM for 3 hours in cell culture media.
• In Vivo Use: Administer 1.5 mg/kg intraperitoneally in rodent models for apoptosis inhibition.
• Controls: Always include DMSO-only and untreated controls to account for vehicle effects.

Conclusion & Outlook

Boc-D-FMK is a validated, broad-spectrum pan-caspase inhibitor for dissecting apoptotic and inflammatory signaling in diverse research models. Its irreversible, cell-permeable action and robust solubility profile make APExBIO’s A1904 formulation a standard in apoptosis and inflammation research. Careful attention to preparation, solubility, and storage underpins reproducible results. Ongoing advances in disease modeling, including cancer and fibrotic disease, are likely to further expand its utility as a benchmark tool for caspase pathway interrogation (IJMS).